Pliant Therapeutics (PLRX)
(Real Time Quote from BATS)
$13.53 USD
+0.08 (0.60%)
Updated Aug 26, 2024 01:02 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Pliant Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 494 | 331 | 201 | 277 | 103 |
Receivables | 0 | 2 | 2 | 9 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 11 | 7 | 7 | 5 | 2 |
Total Current Assets | 506 | 340 | 209 | 291 | 112 |
Net Property & Equipment | 4 | 4 | 5 | 4 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 0 | 1 | 0 | 3 |
Total Assets | 512 | 351 | 221 | 296 | 119 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 2 | 3 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 23 | 20 | 12 | 10 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 29 | 24 | 17 | 12 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 10 | 10 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 1 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 39 | 37 | 22 | 12 | 9 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 186 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 973 | 654 | 414 | 401 | 0 |
Retained Earnings | -500 | -338 | -215 | -118 | -76 |
Other Equity | 0 | -2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 474 | 313 | 199 | 283 | 110 |
Total Liabilities & Shareholder's Equity | 512 | 351 | 221 | 296 | 119 |
Total Common Equity | 474 | 313 | 199 | 283 | -76 |
Shares Outstanding | 59.90 | 48.70 | 36.00 | 35.40 | NA |
Book Value Per Share | 7.91 | 6.43 | 5.53 | 8.00 | 0.00 |
Fiscal Year End for Pliant Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 437 | 482 | 494 | 524 | 555 |
Receivables | 0 | 0 | 0 | 0 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 11 | 8 | 11 | 11 | 9 |
Total Current Assets | 448 | 490 | 506 | 534 | 566 |
Net Property & Equipment | 5 | 6 | 4 | 4 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 0 | 1 |
Total Assets | 484 | 522 | 512 | 540 | 575 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 7 | 5 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 28 | 22 | 23 | 22 | 25 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 31 | 30 | 29 | 27 | 30 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 30 | 30 | 10 | 10 | 10 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 91 | 84 | 39 | 37 | 42 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 996 | 985 | 973 | 964 | 952 |
Retained Earnings | -603 | -547 | -500 | -459 | -417 |
Other Equity | -1 | 0 | 0 | -2 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 393 | 437 | 474 | 503 | 533 |
Total Liabilities & Shareholder's Equity | 484 | 522 | 512 | 540 | 575 |
Total Common Equity | 393 | 437 | 474 | 503 | 533 |
Shares Outstanding | 60.30 | 60.30 | 59.90 | 59.80 | 59.10 |
Book Value Per Share | 6.51 | 7.25 | 7.91 | 8.41 | 9.02 |